Marinus Pharmaceuticals (NASDAQ:MRNS) Upgraded to Outperform by Oppenheimer
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report) was upgraded by research analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a note issued to investors on Monday, MarketBeat.com reports. The firm currently has a $6.00 price objective on the biopharmaceutical company’s stock. Oppenheimer’s price objective would suggest a potential upside of […]
More Stories
Healthcare Realty Trust Incorporated (NYSE:HR) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Healthcare Realty Trust Incorporated (NYSE:HR – Get Free Report) have earned a consensus recommendation of “Hold” from the...
Polaris Inc. (NYSE:PII) Receives Average Rating of “Hold” from Brokerages
Shares of Polaris Inc. (NYSE:PII – Get Free Report) have earned a consensus rating of “Hold” from the eleven ratings...
Head to Head Analysis: Manulife Financial (NYSE:MFC) and New China Life Insurance (OTCMKTS:NWWCF)
New China Life Insurance (OTCMKTS:NWWCF – Get Free Report) and Manulife Financial (NYSE:MFC – Get Free Report) are both financial...
Comparing Carbon Energy (OTCMKTS:CRBOD) and Whiting USA Trust II (OTCMKTS:WHZT)
Carbon Energy (OTCMKTS:CRBOD – Get Free Report) and Whiting USA Trust II (OTCMKTS:WHZT – Get Free Report) are both small-cap...
Contrasting UL Solutions (NYSE:ULS) and NeoGenomics (NASDAQ:NEO)
UL Solutions (NYSE:ULS – Get Free Report) and NeoGenomics (NASDAQ:NEO – Get Free Report) are both mid-cap business services companies,...
Haoxi Health Technology (NASDAQ:HAO) & Stagwell (NASDAQ:STGW) Financial Review
Stagwell (NASDAQ:STGW – Get Free Report) and Haoxi Health Technology (NASDAQ:HAO – Get Free Report) are both small-cap business services...